Skip to main content
Taylor & Francis Group Logo
    Advanced Search

    Click here to search products using title name,author name and keywords.

    • Login
    • Hi, User  
      • Your Account
      • Logout
      Advanced Search

      Click here to search products using title name,author name and keywords.

      Breadcrumbs Section. Click here to navigate to respective pages.

      Chapter

      No Image Available

      Chapter

      Issues in the Neuropsychology of Anxiety

      DOI link for Issues in the Neuropsychology of Anxiety

      Issues in the Neuropsychology of Anxiety book

      Issues in the Neuropsychology of Anxiety

      DOI link for Issues in the Neuropsychology of Anxiety

      Issues in the Neuropsychology of Anxiety book

      ByJeffrey A. Gray
      BookAnxiety and the Anxiety Disorders

      Click here to navigate to parent product.

      Edition 1st Edition
      First Published 1985
      Imprint Routledge
      Pages 22
      eBook ISBN 9780203728215
      Share
      Share

      ABSTRACT

      This chapter aims to draw attention to a number of researchable issues in the neuropsychology of anxiety. Progress in the study of the biological basis of anxiety has been critically dependent on availability of drugs that, clinically, reduce human anxiety. The antianxiety drugs counteract the behavioral effects of three classes of stimuli: stimuli associated with punishment, stimuli associated with the omission of expected reward, and novel stimuli. The more indirect, behavioral approach to the problem suggests that such a critical site of antianxiety drug action is likely to lie in the limbic system. There is abundant evidence that two major classes of antianxiety drugs, the benzodiazepines and the barbiturates, both enhance gamma-aminobutyric acid (GABA)-ergic inhibition; similar observations have been made with ethanol. The increased noradrenergic input may be due to reduced locus coeruleus auto-receptor-mediated inhibition, or to reduced GABAergic presynaptic inhibition of noradrenaline release, or to both; and it may be combined with decreased GABA-ergic control of intrinsic hippocampal neurons.

      T&F logoTaylor & Francis Group logo
      • Policies
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
        • Privacy Policy
        • Terms & Conditions
        • Cookie Policy
      • Journals
        • Taylor & Francis Online
        • CogentOA
        • Taylor & Francis Online
        • CogentOA
      • Corporate
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
        • Taylor & Francis Group
      • Help & Contact
        • Students/Researchers
        • Librarians/Institutions
        • Students/Researchers
        • Librarians/Institutions
      • Connect with us

      Connect with us

      Registered in England & Wales No. 3099067
      5 Howick Place | London | SW1P 1WG © 2022 Informa UK Limited